This STAT+ article, published Aug. 4, 2026 and written by Elaine Chen, opens with a short “need-to-know” section that lists a few corporate earnings items visible on the page, naming Vertex, Pfizer, and Merck. The visible excerpt does not provide further financial figures or analysis.
The publicly visible portion of the article reports that Eli Lilly previously granted a single 79-year-old patient special access to its next‑generation obesity drug retatrutide. Building on that action, Lilly has told STAT that it will now allow other patients to apply for early or special access to the therapy.
The page includes a link to earlier STAT reporting that first described the unusual single‑patient access arrangement. Beyond the short paragraph noting Lilly’s decision to permit applications from additional patients, the visible excerpt does not provide further information about eligibility criteria, application processes, how many additional patients might be allowed, the company’s rationale, anticipated timelines, or any clinical or regulatory context.
Because the article is marked as a STAT+ exclusive, the detailed reporting that would likely address those items is behind the subscription paywall and was not visible in the source excerpt. Those substantive details were not reported in the visible source content and therefore are not summarized here.
The headline and subhead indicate that one of the three items covered in the article is that Gilead won a court case concerning one of its HIV medicines. The publicly visible text on the page does not include any further facts about the litigation: the drug involved, the legal claims at issue, the court and jurisdiction, the ruling’s rationale, potential industry or patient impacts, or next steps.
Because the source excerpt available on the page omitted those specifics and the piece is designated as a STAT+ exclusive, the pertinent details of the Gilead case were not reported in the visible content and are not available to summarize here.
In addition to the two headline items above, the page’s visible elements include a brief earnings note referencing Vertex, Pfizer, and Merck. The article also links to related STAT and STAT+ coverage, including other biotech and industry stories listed under “Most Popular” and “Most Read in STAT+.” Those links point readers to broader STAT reporting on topics such as access to retatrutide, FDA advisory meetings, and other biotech developments.
The visible excerpt does not expand on those earnings items or provide specific results, guidance, or analyst commentary.
This story is published behind STAT’s STAT+ subscription service and is labeled a STAT+ exclusive. The visible portion of the page includes multiple prompts to subscribe or log in to read the rest of the article, and subscription plan pricing and options are shown on the page. Because the detailed reporting for the items in the headline is behind the paywall, the information available in the public excerpt is limited to the headline, byline (Elaine Chen), date (Aug. 4, 2026), a short paragraph on Lilly’s plan to accept applications for retatrutide access, and the indication that Gilead won a legal case concerning an HIV medicine.
Reported in the visible source:
Not reported in the visible source (details that are behind the STAT+ paywall or omitted in the excerpt):
If you have a STAT+ subscription, the full article will contain the in‑depth reporting and particulars on these items. As the source excerpt available here omits those substantive details, this rewrite summarizes only what was visible and states explicitly that additional details were not reported in the source excerpt.